The global leaderboard of wealth: $1.2 Quadrillion of Assets ranked by Market Cap
In-depth research + analysis available with Pro ($3.99/mo) or Pro Plus ($9.99/mo). Everything else on this page is free.
Article
Article
Article
Article
Arcutis Biotherapeutics (ARQT) is gaining momentum as it enters a potential buy zone, fueled by news of an impending FDA decision that could expand its key skin treatment. With four consecutive days of gains, the company is poised for significant growth in the biotech sector, highlighting the importance of innovative treatments for skin disorders. ## BODY: ### Introduction: A Promising Turnaround Arcutis Biotherapeutics (ARQT), a biotech company focused on developing treatments for skin disor
Wharton professor Eric Bradlow emphasizes that the true barrier to effective AI integration in businesses lies not in technology but in organizational change. As companies navigate the complexities of AI, they must rethink workforce structures and develop clear governance to harness AI's full potential. This article delves into the implications of Bradlow’s insights and the broader challenges facing organizations in the age of artificial intelligence. ## BODY: Artificial Intelligence (AI) is o
